An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Diagnostic use
- Acronyms EVOLUTION
- Sponsors Merck Sharp & Dohme
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 5 Sep 2017.
- 12 Jun 2017 Planned End Date changed from 2 Oct 2017 to 1 Sep 2017.